Abstract
The most common PET radioisotopes, both in the literature and in clinical practice, are the cyclotron produced 11C and 18F, giving rise to tracers with minimal chemical changes with respect to the original biological molecule. However, the short half-life of these two radioisotopes and the relatively complex chemistry of their incorporation into the molecules of interest limits the number of molecules that really can be labelled in a suitable length of time. 68Ga is a positron emitter, produced by a 68Ge/68Ga generator rending the production of its radiopharmaceuticals independent of an onsite cyclotron. This paper covers the main aspects of the Ga3+ coordination chemistry together with the state of art of its radiopharmacy.
Keywords: Bioconjugates, PET imaging, nuclear probes, 68Ge/68Ga generator, gallium-68, MSH, Peptides, Imaging, Antibodies
Current Radiopharmaceuticals
Title: Gallium-68: A New Trend in PET Radiopharmacy
Volume: 5 Issue: 2
Author(s): M. Isabel M. Prata
Affiliation:
Keywords: Bioconjugates, PET imaging, nuclear probes, 68Ge/68Ga generator, gallium-68, MSH, Peptides, Imaging, Antibodies
Abstract: The most common PET radioisotopes, both in the literature and in clinical practice, are the cyclotron produced 11C and 18F, giving rise to tracers with minimal chemical changes with respect to the original biological molecule. However, the short half-life of these two radioisotopes and the relatively complex chemistry of their incorporation into the molecules of interest limits the number of molecules that really can be labelled in a suitable length of time. 68Ga is a positron emitter, produced by a 68Ge/68Ga generator rending the production of its radiopharmaceuticals independent of an onsite cyclotron. This paper covers the main aspects of the Ga3+ coordination chemistry together with the state of art of its radiopharmacy.
Export Options
About this article
Cite this article as:
Isabel M. Prata M., Gallium-68: A New Trend in PET Radiopharmacy, Current Radiopharmaceuticals 2012; 5 (2) . https://dx.doi.org/10.2174/1874471011205020142
DOI https://dx.doi.org/10.2174/1874471011205020142 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Preparation and <I>In Vitro/Vivo</I> Evaluation of Folate-conjugated Pluronic F87-PLGA/TPGS Mixed Nanoparticles for Targeted Drug Delivery
Current Drug Delivery Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Protective Role of Natural Products in Glioblastoma Multiforme: A Focus on Nitric Oxide Pathway
Current Medicinal Chemistry Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design STAT3 Regulation of Glioblastoma Pathogenesis
Current Molecular Medicine Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Stressed to Death: Targeting Endoplasmic Reticulum Stress Response Induced Apoptosis in Gliomas
Current Pharmaceutical Design Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design